Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...